vs

Side-by-side financial comparison of Information Services Group Inc. (III) and MEDIFAST INC (MED). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $61.2M, roughly 1.2× Information Services Group Inc.). On growth, Information Services Group Inc. posted the faster year-over-year revenue change (2.7% vs -36.9%). Over the past eight quarters, Information Services Group Inc.'s revenue compounded faster (-2.4% CAGR vs -34.4%).

EBSCO Information Services, headquartered in Ipswich, Massachusetts, is a division of EBSCO Industries Inc., a private company headquartered in Birmingham, Alabama. EBSCO provides products and services to libraries of many types around the world. Its products include EBSCONET, a complete e-resource management system, and EBSCOhost, which supplies a fee-based online research service with 375 full-text databases, a collection of 600,000-plus ebooks, subject indexes, point-of-care medical refere...

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

III vs MED — Head-to-Head

Bigger by revenue
MED
MED
1.2× larger
MED
$75.1M
$61.2M
III
Growing faster (revenue YoY)
III
III
+39.6% gap
III
2.7%
-36.9%
MED
Faster 2-yr revenue CAGR
III
III
Annualised
III
-2.4%
-34.4%
MED

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
III
III
MED
MED
Revenue
$61.2M
$75.1M
Net Profit
$2.7M
Gross Margin
69.4%
Operating Margin
8.2%
-10.4%
Net Margin
4.4%
Revenue YoY
2.7%
-36.9%
Net Profit YoY
82.5%
EPS (diluted)
$0.05
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
III
III
MED
MED
Q1 26
$61.2M
Q4 25
$61.2M
$75.1M
Q3 25
$62.4M
$89.4M
Q2 25
$61.6M
$105.6M
Q1 25
$59.6M
$115.7M
Q4 24
$57.8M
$119.0M
Q3 24
$61.3M
$140.2M
Q2 24
$64.3M
$168.6M
Net Profit
III
III
MED
MED
Q1 26
$2.7M
Q4 25
$2.6M
Q3 25
$3.1M
$-2.3M
Q2 25
$2.2M
$2.5M
Q1 25
$1.5M
$-772.0K
Q4 24
$3.0M
Q3 24
$1.1M
$1.1M
Q2 24
$2.0M
$-8.2M
Gross Margin
III
III
MED
MED
Q1 26
Q4 25
44.8%
69.4%
Q3 25
42.2%
69.5%
Q2 25
42.2%
72.6%
Q1 25
43.1%
72.8%
Q4 24
41.5%
74.1%
Q3 24
40.4%
75.4%
Q2 24
39.5%
73.2%
Operating Margin
III
III
MED
MED
Q1 26
8.2%
Q4 25
8.4%
-10.4%
Q3 25
7.4%
-4.6%
Q2 25
7.6%
-1.0%
Q1 25
5.7%
-1.1%
Q4 24
0.3%
0.6%
Q3 24
7.0%
1.5%
Q2 24
5.7%
-4.7%
Net Margin
III
III
MED
MED
Q1 26
4.4%
Q4 25
4.3%
Q3 25
4.9%
-2.5%
Q2 25
3.5%
2.3%
Q1 25
2.5%
-0.7%
Q4 24
5.3%
Q3 24
1.9%
0.8%
Q2 24
3.2%
-4.8%
EPS (diluted)
III
III
MED
MED
Q1 26
$0.05
Q4 25
$0.06
$-1.64
Q3 25
$0.06
$-0.21
Q2 25
$0.04
$0.22
Q1 25
$0.03
$-0.07
Q4 24
$0.07
$0.08
Q3 24
$0.02
$0.10
Q2 24
$0.04
$-0.75

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
III
III
MED
MED
Cash + ST InvestmentsLiquidity on hand
$167.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$198.9M
Total Assets
$248.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
III
III
MED
MED
Q1 26
Q4 25
$28.7M
$167.3M
Q3 25
$28.7M
$173.5M
Q2 25
$25.2M
$162.7M
Q1 25
$20.1M
$164.6M
Q4 24
$23.1M
$162.3M
Q3 24
$9.7M
$170.0M
Q2 24
$11.8M
$163.5M
Stockholders' Equity
III
III
MED
MED
Q1 26
Q4 25
$94.7M
$198.9M
Q3 25
$94.7M
$214.7M
Q2 25
$94.1M
$216.0M
Q1 25
$95.0M
$211.0M
Q4 24
$96.3M
$210.1M
Q3 24
$96.6M
$207.3M
Q2 24
$95.5M
$205.3M
Total Assets
III
III
MED
MED
Q1 26
Q4 25
$211.0M
$248.0M
Q3 25
$213.3M
$268.2M
Q2 25
$200.7M
$269.3M
Q1 25
$202.4M
$280.0M
Q4 24
$204.5M
$284.2M
Q3 24
$227.1M
$291.2M
Q2 24
$235.3M
$293.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
III
III
MED
MED
Operating Cash FlowLast quarter
$-5.3M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
III
III
MED
MED
Q1 26
Q4 25
$5.1M
$-5.3M
Q3 25
$11.1M
$12.1M
Q2 25
$11.9M
$-3.4M
Q1 25
$978.0K
$3.4M
Q4 24
$6.6M
$-4.9M
Q3 24
$8.8M
$9.1M
Q2 24
$2.2M
$13.1M
Free Cash Flow
III
III
MED
MED
Q1 26
Q4 25
$4.3M
$-6.6M
Q3 25
$9.5M
$10.8M
Q2 25
$11.1M
$-4.8M
Q1 25
$141.0K
$1.9M
Q4 24
$6.0M
$-7.2M
Q3 24
$8.4M
$7.7M
Q2 24
$1.3M
$11.1M
FCF Margin
III
III
MED
MED
Q1 26
Q4 25
7.0%
-8.8%
Q3 25
15.2%
12.0%
Q2 25
18.0%
-4.5%
Q1 25
0.2%
1.6%
Q4 24
10.4%
-6.1%
Q3 24
13.7%
5.5%
Q2 24
2.0%
6.6%
Capex Intensity
III
III
MED
MED
Q1 26
Q4 25
1.2%
1.8%
Q3 25
2.5%
1.5%
Q2 25
1.4%
1.3%
Q1 25
1.4%
1.3%
Q4 24
0.9%
1.9%
Q3 24
0.6%
1.0%
Q2 24
1.4%
1.1%
Cash Conversion
III
III
MED
MED
Q1 26
Q4 25
1.94×
Q3 25
3.62×
Q2 25
5.46×
-1.36×
Q1 25
0.66×
Q4 24
2.15×
Q3 24
7.66×
8.04×
Q2 24
1.07×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons